Status:
TERMINATED
Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.
Lead Sponsor:
Nghi Nguyen
Collaborating Sponsors:
Blue Earth Diagnostics
Conditions:
Cervical Cancer
Uterine Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
18F Fluciclovine is a recently FDA- approved radiopharmaceutical for prostate cancer biochemical recurrence, which is only minimally eliminated by the kidneys and therefore the image interpretation is...
Detailed Description
Background: Endometrial cancer arises from the inner lining of the uterus and is one of the most common malignancies in women, representing 3.6% of all new cancer cases in the US. It is estimated tha...
Eligibility Criteria
Inclusion
- Female
- 18 years and older
- Biopsy-proved cervical cancer or endometrial cancer within three months of study enrollment
- Standard-of-care (SOC) FDG PET/CT exam performed within 30 days of study enrollment
Exclusion
- Female \< 18 years old
- No history of cervical cancer or endometrial cancer
- Primary biopsy \> 3 months of study enrollment
- Systemic therapy or radiation therapy initiated
- SOC FDG PET/CT exam performed \> 30 days of study enrollment
- Therapeutic procedures (chemotherapy, radiation therapy) have been initiated
- Pregnancy or lactation
- Claustrophobia or inability to tolerate the imaging procedure on the PET/MR scanner
- Individual is not willing to give informed consent
Key Trial Info
Start Date :
December 11 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2019
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03423082
Start Date
December 11 2018
End Date
December 18 2019
Last Update
October 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Presbyterian - MR Research Center
Pittsburgh, Pennsylvania, United States, 15213